Malaria remains one of the deadliest infectious diseases on the planet, claiming over 600,000 lives annually and locking entire regions into cycles of poverty, illness, and economic stagnation. Despite decades of intervention, we remain trapped in a frustrating pattern: short-term solutions that require constant renewal, leaving vulnerable populations exposed.

At Eyam Health, we believe it’s time to break this cycle. Not just mitigate malaria, but eradicate it completely. Not just contain outbreaks, but transform how we think about biologics and global health interventions.

Since September of last year, we’ve been advancing a study with the Gates Foundation on a long-acting monoclonal antibody (mAb) therapy powered by Gemini—that has the potential to disrupt malaria prevention and revolutionize how the world deploys biologics at scale.

Why Malaria Persists: The Economic Burden of an Unsolved Crisis

Malaria is not just a public health issue; it is a massive economic drain. Countries struggling with endemic malaria face structural economic challenges that keep them from reaching their full potential. The disease’s impact extends far beyond individual infections:

• Lost Workforce Productivity: Malaria results in millions of missed workdays annually, reducing GDP in affected countries by up to 1.3% each year. Chronic reinfections keep individuals out of the workforce, stagnating economic development.

• Educational Disruptions: Children who suffer from repeated malaria infections experience cognitive impairments and higher rates of school absenteeism, limiting their future earnings and reinforcing cycles of poverty.

• Strained Healthcare Systems: Governments spend billions treating malaria, diverting resources from other critical healthcare needs. The disease disproportionately affects the most vulnerable populations, widening global health inequalities.

• Reduced Foreign Investment: Investors are hesitant to expand operations in malaria-endemic regions. However, countries that have successfully eliminated malaria—like Sri Lanka and Paraguay—have seen a surge in economic growth and foreign direct investment.

Eliminating malaria is not just a humanitarian mission—it’s an economic imperative.

Why Current Malaria Strategies Are Insufficient

Despite major efforts, existing malaria prevention methods are falling short:

• Bed nets and insecticides require constant distribution and replacement, yet insecticide resistance is rising.

• Seasonal chemoprevention helps reduce cases but does not offer long-term protection.

• Current malaria vaccines (RTS,S and R21) provide only partial protection, with efficacy dropping below 50% within a year. These vaccines require multiple booster doses, making them difficult to deploy at scale.

The reality is that today’s approaches fail to provide durable, cost-effective, and easily scalable protection. We need a longer-lasting solution that delivers real immunity without the burden of constant re-administration.

Gemini-Powered Monoclonal Antibodies for Malaria

Last month we announced interim results from our Gates Foundation funded study, and the data continues to show strong, sustained, long-lasting results.

🔹 What Makes Our Approach Different?

• High Antibody Production: Our latest study demonstrates high antibody production beyond four months – outperforming key benchmarks and showing the potential to replace multiple rounds of seasonal interventions.

• Immediate Protection: Unlike traditional vaccines that take weeks to build immunity, mAbs work immediately, making them highly effective for outbreak response.

• Longer Durability: With Gemini-enabled stability, these mAbs aim to provide six months or more of protection, dramatically reducing the need for frequent dosing.

The Gemini Platform: Unlocking the Next Generation of Biologics

At the heart of this work is Gemini, Eyam’s novel delivery platform that is helping to redefine how biologics are delivered. Traditional monoclonal antibody therapies have always been limited by cost, cold-chain dependence, and frequent dosing schedules—but Gemini aims to solve these problems:

🔹 Lower Costs & Scalability: Traditional mAbs are expensive to produce and distribute. Gemini reduces manufacturing costs by orders of magnitude, making large-scale deployment feasible.

🔹 Extended Duration of Protection: Unlike conventional mAbs, which require multiple doses to maintain protection, Gemini-enhanced biologics strives to offer sustained antibody expression, ensuring longer-lasting immunity.

🔹 Reducing the Need for Cold Chain Storage: Traditional biologics depend on strict cold-chain logistics, creating massive barriers in rural and resource-limited settings. Gemini’s high stability strives to make these life-saving therapies more accessible.

This isn’t just a malaria solution—this is a blueprint for how we tackle biologics across multiple disease areas.

Beyond Malaria: The Future of Long-Lasting Monoclonal Antibodies

The implications of Gemini-enabled mAbs extend far beyond malaria. This technology is highly translatable to other disease areas, unlocking multi-billion-dollar market opportunities:

1. Infectious Diseases

• Tuberculosis (TB): The current TB vaccine offers limited protection, and the $1.5B global TB market lacks long-term solutions. Gemini mAbs could change that.

• HIV/AIDS: The $30B+ HIV market is dominated by daily antiretrovirals. Long-acting mAbs could simplify treatment and prevention.

• Influenza & RSV: Seasonal vaccines require constant updates (costing $6–8B annually). Durable mAbs could offer year-round protection.

2. Chronic Diseases

• Autoimmune Disorders: The $65B+ autoimmune biologics market depends on frequent injections. Long-duration mAbs could revolutionize patient care.

• Oncology: Cancer therapies require repeated dosing. Gemini mAbs could enable multi-target cancer vaccines, disrupting the $500B oncology market.

3. Animal Health

• Veterinary monoclonal antibodies are an emerging market, particularly in livestock and companion animal treatments.

• The $12B global animal vaccine market is ripe for disruption with Gemini-powered long-acting biologics.

Investing in the Future of Malaria Eradication

The opportunity to eradicate malaria and revolutionize biologics is here—but it requires investment, collaboration, and action.

• Governments & NGOs must prioritize funding for durable biologics to move beyond temporary fixes.

• Investors have the chance to back a technology with enormous potential beyond malaria—including infectious diseases, chronic illnesses, and oncology.

• Eyam Health is actively seeking partners to accelerate the deployment of Gemini-enabled mAbs, ensuring they reach the communities that need them most.

This isn’t just another biotech innovation. This is a new paradigm for global health.

Together, we can move beyond short-term fixes and toward a future where durable biologics redefine disease prevention worldwide.

Let’s make history.